文献速递临床免疫

新型自动化颗粒多分析物检测法在原发性胆汁性胆管炎自身抗体检测中的评估

Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis.
PubMed 文献 · Clin Chem Lab Med · 2020-04-10

该研究在194例原发性胆汁性胆管炎(PBC)患者和138例疾病对照中,用Aptiva仪器上的新型颗粒多分析物技术(PMAT)检测MIT3、sp100、gp210、HK1和KLp抗体。在AMA-IIF阴性PBC队列中,各标志物特异性>95%时敏感性分别为20.6%、16.2%、23.5%、22.0%和13.2%,联合检测使总敏感性从53%升至61.8%。

要点

  • PMAT法可检测MIT3、sp100、gp210、HK1和KLp五种PBC相关抗体。
  • 在AMA-IIF阴性PBC中,联合新标志物使敏感性从53%升至61.8%。
  • 8.8%的AMA-IIF阴性血清仅HK1或KLp抗体阳性。

核心结论

  • Aptiva-PMAT技术可识别比传统免疫分析更多的AMA阴性PBC患者。

研究设计与样本

  • 研究纳入194例PBC患者(126例AMA-IIF阳性,68例AMA-IIF阴性)和138例疾病对照,用Aptiva仪器上的PMAT法检测MIT3、sp100、gp210、HK1和KLp抗体。

主要发现

  • 在特异性>95%的截断值下,AMA-IIF阴性PBC队列中抗MIT3、抗sp100、抗gp210、抗HK1和抗KLp的敏感性分别为20.6%、16.2%、23.5%、22.0%、17.6%和13.2%。
  • 68例AMA-IIF阴性血清中6例(8.8%)仅抗HK1或抗KLp阳性。
  • 在抗MIT3、抗sp100和抗gp210基础上加入新标志物,使该队列总敏感性从53%升至61.8%。

关键数值与推荐

  • 所有标志物截断值选择 yielding 特异性>95%。
  • 抗MIT3、抗sp100、抗gp210、抗HK1和抗KLp在AMA-IIF阴性PBC中的敏感性分别为20.6%、16.2%、23.5%、22.0%、17.6%和13.2%。
  • 联合检测使AMA-IIF阴性PBC的总敏感性从53%提高到61.8%。

临床怎么用

  • PMAT法可用于检测PBC相关自身抗体谱,提高AMA阴性PBC的血清学检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-mitochondrial autoantibodies (AMA) detected by indirect immunofluorescence (IIF) on rodent tissues are the diagnostic marker of primary biliary cholangitis (PBC). However, up to 15% of patients with PBC are AMA-negative by IIF. In the effort to close the serological gap and improve the diagnostic sensitivity of PBC testing, recently, novel autoantibodies specific for PBC, such as kelch-like 12 (KLHL12, KLp epitope) and hexokinase 1 (HK1) have been described. In this study, we evaluated the autoantibody profile in a large cohort of PBC patients and in patients with other liver disease, including anti-HK1 and anti-KLp autoantibodies. METHODS: Sera of 194 PBC patients (126 AMA-IIF-positive and 68 AMA-IIF-negative) and 138 disease controls were tested for a panel of PBC-specific antibodies (MIT3, sp100, gp210, HK1, KLp) using a new automated particle-based multi-analyte technology (PMAT) assay on the Aptiva instrument (Inova). RESULTS: Selecting a cutoff yielding a specificity of >95% for all the markers, the sensitivity for anti-MIT3, anti-sp100, anti-gp210, anti-HK1 and anti-KLp in the PBC AMA-IIF-negative cohort was 20.6%, 16.2%, 23.5%, 22.0%, 17.6 and 13.2%, respectively. Six out of the 68 (8.8%) AMA-IIF negative sera were positive for anti-HK1 or anti-KLp alone. Using these new markers in addition to anti-MIT3, anti-sp100 and anti-gp210, the overall sensitivity in this cohort of AMA-IIF-negative patients increased from 53% to 61.8%, reducing the serological gap in AMA-negative PBC patients. CONCLUSIONS: PBC antibody profiling, made possible by the new Aptiva-PMAT technology, allows recognition of a higher number of AMA-negative PBC patients than conventional immunoassays and may represent a useful tool to evaluate the prognostic significance of autoantibody association in PBC patients.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Villalta D, Seaman A, Tiongson M, et al. Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis. Clin Chem Lab Med. 2020. PMID: 32286240. doi:10.1515/cclm-2020-0122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。